Garivulimab

Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody that specifically targets and binds to PD-L1. Garivulimab selectively blocks the interaction of PD-L1 and PD-1. Garivulimab has antitumor activity[1].

Signaling Pathways >> Apoptosis >> Apoptosis

Research Areas >> Cancer

Signaling Pathways >> Immunology/Inflammation >> PD-1/PD-L1

Garivulimab (BGB-A333) specifically targets and binds to PD-L1, blocking interaction to its receptor, PD-1 on T cell, reversing T cell inactivation, and increases T cell expansion resulting in cytotoxic T cell-mediated antitumor immune response against PD-L1-expressing tumor cells. Garivulimab also inhibits PD-L1-induced apoptosis of activated CD8+ T cells and increases T cell proliferation[1].